MIST - Milestone Pharmaceuticals Inc Stock Price, Fair Value and News

$2.62-0.03 (-1.13%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MIST Price Action

Last 7 days

0.4%

Last 30 days

41.6%

Last 90 days

47.2%

Trailing 12 Months

40.9%

MIST RSI Chart

MIST Valuation

Market Cap

223.1M

Price/Earnings (Trailing)

-3.85

Price/Sales (Trailing)

163.53

EV/EBITDA

-3.58

Price/Free Cashflow

-5.17

MIST Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MIST Fundamentals

MIST Revenue

Revenue (TTM)

1.0M

MIST Earnings

Earnings (TTM)

-58.0M

Earnings Growth (Yr)

-26.31%

Earnings Growth (Qtr)

8.05%

MIST Profitability

EBT Margin

-5177.10%

Return on Equity

-282.97%

Return on Assets

-66.11%

Free Cashflow Yield

-19.34%

MIST Investor Care

Shares Dilution (1Y)

59.71%

Diluted EPS (TTM)

-0.81

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	0	0	0	0
2023	5.5M	6.0M	4.5M	1.0M
2022	11.7M	0	8.3M	5.0M
2021	4.3M	7.9M	11.4M	15.0M
2020	2.5M	2.0M	1.2M	726.0K
2019	1.2M	1.7M	2.1M	2.6M
2018	0	0	0	711.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in MontrÃƒÆ’Ã‚Â©al, Canada.

CEO	Mr. Joseph G. Oliveto M.B.A.
WEBSITE	milestonepharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	39

Milestone Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Milestone Pharmaceuticals Inc? What does MIST stand for in stocks?

MIST is the stock ticker symbol of Milestone Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Milestone Pharmaceuticals Inc (MIST)?

As of Wed Dec 03 2025, market cap of Milestone Pharmaceuticals Inc is 223.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MIST stock?

You can check MIST's fair value in chart for subscribers.

Is Milestone Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MIST is over valued or under valued. Whether Milestone Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Milestone Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MIST.

What is Milestone Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, MIST's PE ratio (Price to Earnings) is -3.85 and Price to Sales (PS) ratio is 163.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MIST PE ratio will change depending on the future growth rate expectations of investors.